Iovance Biotherapeutics logo Clinical Trials

Iovance is currently evaluating lifileucel in clinical studies for its potential to address melanoma, non-small cell lung cancer (NSCLC), gynecologic cancers, and other cancers.

Learn about our ongoing TIL cell therapy trials to create new possibilities for your patients.

TIL=tumor infiltrating lymphocytes.

Featured Trials

Non-small cell lung cancer trial icon

IOV-LUN-202:

Non-Small Cell Lung Cancer (NSCLC)

A Phase 2, multicenter trial in patients with metastatic NSCLC with disease progression following chemoimmunotherapy

View trial
Advanced melanoma trial icon

TILVANCE-301:

Advanced Melanoma

A Phase 3, multicenter trial in patients with unresectable or metastatic melanoma with no prior therapy for metastatic disease

View trial
View more trials

About Iovance Biotherapeutics

Iovance Biotherapeutics is working to become a global leader in the development and delivery of TIL cell therapy. We are finding new ways to help the body’s own immune system find and fight cancer. This therapy has already shown promising results in solid tumors.

Learn more about investigational
TIL cell therapy

Explore the science

This website is intended for a U.S. audience. TIL cell therapy is not yet approved by any regulatory or health agency for the investigational uses described in this website. This website is for educational purposes only and is not intended to replace discussions with a healthcare professional.